Trials
3 active
3 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Pompe Disease (3 trials)
- Main trialPhase 2
- “The purpose of this study is to evaluate the safety, pharmacodynamics (PD), and exploratory clinical efficacy of S-606001 in adult participants with LOPD as an add-on to ERT.”In the company’s words, NCT07123155 on ClinicalTrials.gov
Other drugs for Pompe Disease
- Cipaglucosidase AlfaAmicus Therapeutics · Phase 3
- DNL952Denali Therapeutics Inc. · Phase 1/2
- Avalglucosidase alfaSanofi · Marketed (Phase 4 trial)
Coming up3
- 8 Aug 2027Phase 2 trial completes · ClinicalTrials.gov
- 31 Aug 2028Phase 2 trial completes · ClinicalTrials.gov
- 31 Oct 2028Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 8 Aug 2027 | Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD) | |
| Phase 2Not yet recruiting | 31 Aug 2028 | An Extension Study of S-606001 in Participants With Late-onset Pompe Disease (LOPD) | |
| Phase 1Not yet recruiting | 31 Oct 2028 | A Study of S-606001 as Monotherapy in Participants With Late-onset Pompe Disease (LOPD) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026